ACD/Labs Opens new Office in the UK
News Jan 04, 2006
Advanced Chemistry Development, Inc. has announced that they are expanding their direct presence in Europe by opening an office in the United Kingdom.
The new office in the UK will serve local pharmaceutical, chemical, environmental, and academic markets, providing customers with direct access to ACD/Labs’ technical sales, support, and software development services.
The UK office will be initially staffed with a team of professionals who have in-depth knowledge of the region, and who are already experienced with ACD/Labs products.
ACD/Labs will now be able to offer a complete range of business and technical services, and provide a faster response to the needs of their customers.
The United Kingdom has traditionally been an important market for ACD/Labs’ specialty software products for analytical, organic, and other areas of chemistry, with installations at many leading chemical and pharmaceutical R&D organizations.
Val Kulkov, President of ACD/Labs, states, "Our new office in England will allow us to directly serve our customers in the UK and Ireland. This exciting new opportunity will enhance our collaboration with clients in a key chemical and pharmaceutical R&D region – the United Kingdom."
Guy Desmarquets, ACD/Labs Director of European Operations, adds, "The new UK office will deliver even better care to our customers."
"Europe will now be served by a team composed of ACD/Labs sales and application specialists in the UK and Ireland, with distributors providing service in local languages in the rest of the continent."
"With this strategy, our wide and diverse community of customers in Europe will continue to benefit from high quality sales and support services."
With the introduction of the UK office, Advanced Chemistry Development will now conduct direct business in North America, India, and the UK and Ireland.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE